Affordable antiretroviral drugs for the under-served markets: How to expand equitable access against the backdrop of challenging scenarios?

Current HIV Research

Volumn 4, Issue 1, 2006, Pages 3-20

  Dionisio, Daniele ^a   Cao, Yunzhen ^b   Hongzhou, Lu ^c   Kraisintu, Krisana ^d,e   Messeri, Daniela ^a  

^a PISTOIA HOSPITAL   (Italy)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c FUDAN UNIVERSITY   (China)

^d Global Campaign for Education   (Germany)

^e Tanzania Pharmaceutical Industries ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTEMISININ DERIVATIVE; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GENERIC DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CHINA; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC DEVELOPMENT; EPIDEMIC; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEPATITIS C; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; INFECTION CONTROL; INFECTION RISK; INTERNATIONAL COOPERATION; INTRAVENOUS DRUG ABUSE; LEGAL ASPECT; MALARIA; MEDICAL ETHICS; PATENT; PHARMACEUTICAL CARE; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; THAILAND; TUBERCULOSIS; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; COMMERCIAL PHENOMENA; DEVELOPING COUNTRY; ECONOMICS; HEALTH SERVICE; POVERTY;

ANTI-HIV AGENTS; COMMERCE; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HUMANS; INTELLECTUAL PROPERTY; INTERNATIONAL COOPERATION; PATENTS; POVERTY; WORLD HEALTH ORGANIZATION;

EID: 33644896565     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016206775197592     Document Type: Review

References (74)

1. AIDS Drugs Threatened (March 5, 2005 Editorial). New York Times http://www.nytimes.com/2005/03/05/opinion/05sat3.html.
2. AIDS Epidemic update (December 2004) http://www.unaids.org/wad2004/EPI_1204_pdf_en/ Chapter3_subsaharan_africa_en.pdf.
3. AIDS in Africa: three scenarios to 2025 (2005) UNAIDS http://www.unaids.org/en/AIDS+in+Africa_Three+scenarios+to+2025.asp.
4. AIDS in Tanzania (2005) http://www.tanzaniacare.org/htmls/AIDS_tanzania.html.
5. (a) AIDS Medicines and Diagnostics Service-AMDS (2005) http://www.who.int/3by5/amds/en/.
6. (b) Aspen and India's Matrix Sign JVs (2005) http://www.Aspenpharma.com/showarticle.php?id=210.
7. Breman JG, Egan A, Keusch GT. (2001). The intolerable burden of malaria: a new look at the numbers. The American Journal of Tropical Medicine and Hygiene Jan-Feb 64 (1-2 Suppl): iv-vii.
8. Cao Y. (2002). Epidemiology and prevention of HIV/AIDS in China. Foreign Medical Sciences (Epidemiology and infections) 29: 1-3.
9. Cao Y, Li G, Wang S, Cheng H, Sun F, Zhou F, He Y. (2002). Epidemiology, crisis and strategy on HIV mother-to-infant transmission in China. Chinese Journal of Infectious Diseases 20;3:185-188.
10. Cao Y, Zhang F, Mei S, Li L, Gao M, Ding Y, Cai W. (2002). The first clinical trial in China using triple therapy Combivir plus Indinavir in patients with HIV-1 infection. Chinese Medical Journal, Electronic Version Vol.115. No.10 www.cmj.org.
11. Chen Z. (2004). Finding a cure for medical system. China Daily 09/15/ 2005 page 5 http://www.chinadaily.com.cn/english/doc/2004-09/15/content_374491.htm.
12. China's medium- & long-term strategy for HIV/AIDS prevention and control (1998-2010). http://www.chinaids.org.cn/zhq/index.asp.
13. Clinton HIV/AIDS Initiative (2004). The people's republic of China signs agreement with Clinton HIV/AIDS Initiative to develop nationwide care and treatment plan http://www.clintonpresidentialcenter.org/ 042904-nr-chai-china-agreement.htm.
14. Demographic and Socio-economic Information (2004) http://www.afro.who.int/malaria/country-profile/tanzania.pdf.
15. Department for International Development (March 2005). Increasing people's access to essential medicines in developing countries: a framework for good practice in the pharmaceutical industry. A UK Government policy paper http://www.dfid.gov.uk/pubs/files/pharm-framework.pdf.
16. Doha Declaration on TRIPS and Public Health (November 2001) http://www.wto.org/english/thewto_e/minist_e/min01_e/ mindecl_trips_c.htm.
17. Druce N. (2004). Acces to medicines in under-served markets: what are the implications of changes in intellectual property rights, trade and drug registration policy? DFID Health Systems Resource Centre http://www.dfidhealthrc.org/shared/know_the/publications.html#access.
18. Dutfield G, Suthersanen U. (August 2004). Harmonisation or Differentiation in Intellectual Property Protection? The lessons of history. Quaker United Nations Office, occasional paper 15 http://www.geneva.quno.info/pdf/OP15.pdf.
19. Dutfield G. (March 11, 2005). The US and Europe are "intellectual property fundamentalists". Science and Development Network (SciDevNet) http://www.scidev.net.
20. Furber AS, Hodgson IJ, Desclaux A, Mukasa DS. (2004). Barriers to better care for people with AIDS in developing countries. British Medical Journal 329: 1281-1283.
21. Global Fund to Fight AIDS, TB and Malaria (2004). China can avert major AIDS crisis and beat TB epidemic http://www.theglobalfund.org/en/media_center/press/pr_041207.asp.
22. Global Fund to Fight AIDS, TB and Malaria (2004). China signs $32 million AIDS grant with Global Fund http://www.theglobalfund.org/en/media_center/press/pr_040819.asp.
23. Government Pharmaceutical Organization (May 2005) http://www.gpo.or.th.
24. Grace C (2004). The effect of changing intellectual property on pharmaceutical industry prospects in India and China: considerations for access to medicines. DFID Health Systems Resource Centre http://www.dfidhealthrc.org/shared/know_the/publications.html#access.
25. Gray A. (2004). Access to Medicines and Drug Regulation in Developing Countries: a Resource Guide for DFID. DFID Health Systems Resource Centre. http://www.ihsd.org/learning/project-feb05.htm.
26. Guimier JM, Lee E, Grupper M. (2004). Processes and issues for improving access to medicines: the evidence base for domestic production and greater access to medicines. DFID Health Systems Resource Centre http://www.dfidhealthrc.org/shared/publications/Issues_papers/ATM/ Guimier.pdf.
27. Gwatkin DR, Bhuiya A, Victors, CG. (2004). Making Health Systems more Equitable. The Lancet 364: 1273-1280.
28. Health GAP Global Access Project (February 2005). The impact of India's Amended Patents Act on access to affordable HIV treatment http://www.healthgap.org.
29. Health GAP Global Access Project (March 6, 2005). India could cut-off Africa's access to affordable AIDS drugs http://www.healthgap.org/press_releases/05/030104_HGAP_AA_INDIA_IPR.html.
30. Health GAP Global Access Project (February 10, 2005). Response to USTR fact sheet on CAFTA and access to medicines http://www.healthgap.org.
31. Health GAP Global Access Project (March 15, 2005). To: The Group of 7 Heads of State http://www.healthgap.org/press_releases/05/031505_HGAP_LTR_G7_memorandum.
32. HIV/AIDS Situation in Thailand (2004) http://www.epid.moph.go.th.
33. http://www.chinadaily.com.cn/english/doc/2004-06/28/content_343452.htm.
34. http://www.wipo.int/about-wipo/en/gib.htm.
35. ICTSD Bridges (vol.9 number 4, 9 February 2005).US quietly promotes patent harmonisation at developed country meeting: http://www.ictsd.org/weekly/05-02-09/story5.htm.
36. ICTSD Bridges (vol. 9 number 1, 19 January 2005). Indian TRIPS-compliance legislation under fire: http://www.ictsd.org/weekly/05-01-19/story2.htm.
37. ICTSD Bridges (vol. 9 number 10, 23 March 2005). Indian Parliament approves controversial patent bill http://www.ictsd.org/weekly/05-03-23/story1.htm.
38. Lewis-Lettington R. (2005). Personal opinion: Reflections on the Relevance of Law. Institute for Health Sector Development (IHSD) http://www.ihsd.org/learning/project-feb05.htm.
39. Lewis-Lettington R, Banda C. (2004). A survey of policy and practice on the use of access to medicines-related TRIPS flexibilities in Malawi. DFID Health Systems Resource Centre http://www.dfidhealthrc.org/shared/know_the/publications.html#access.
40. Lewis-Lettington R, Munyi P. (2004). Willingness and ability to use TRIPS flexibilities: Kenia case study. DFID Health Systems Resource Centre http://www.dfidhealthrc.org/shared/know_the/publications.html#access.
41. Li L, Wei F, Mei S, Feng X, Yao J, Jin X, Cao Y. (2004). Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks. Chinese Medical Journal 117; 3:347-352.
42. Li L, Wei F, Mei S, Feng X, Yao J, Cao Y, Jin X. (2002). 48 Weeks follow-up The Virological and Immunological Outcomes in Combination Therapy with Efavirenz and Indinavir in HIV-1 Infections in China. Chinese Journal of STD/AIDS Prevention and Control 8:326-330.
43. Li L, Wei F, Mei S, Feng X, Cao Y, Jin X. (11-16 July 2004) The impact of HAART on immunological parameters in HIV-1-infected Chinese. International AIDS Conference, Bangkok, MOPE A 3010.
44. (a) Li X, Cheng H, He J, Zhang F, Jia M, Zhang J, Zong Y, Huang J, Cui W, Wang L, Tang M, Liu X, Ma Y, Chen X, Diao J, Cao Y. (2001). A clinical report on 482 AIDS cases. Chinese Journal of Infection and Chemotherapy 1: 129-132.
45. (b) Loi signed by MSD and Aspen for generic ARV license for Efavizenz (2005). http:www.Aspenpharma.com/showarticle.php?id=208.
46. Médecins sans Frontières (February 2005). Will the lifeline of affordable medicines for poor countries be cut? Consequences of medicines patenting in India (briefing document) http://www.accesmed-msf.org.
47. Medical News Today (17 March 2005). Brazil requests voluntary licensing for AIDS drugs to treat more patients, reduce costs of importing patented drugs http://www.medicalnewstoday.com/medicalnews.php?newsid=21378.
48. (a) Millennium Project Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines. Working Group on HIV/AIDS (2005). Combating AIDS in the developing world http://www.unmillenniumproject.org/documents/HIVAIDS-complete.pdf.
49. (b) PE's Aspen signs up to produce US AIDS drugs (2005). http:www.theherald.co.za/herald/2005/04/26/biz/02_26042005.htm.
50. Physicians for Human Rights (2004). Health Professionals Urge Debt Cancellation for Poor Countries http://www.phrusa.org/campaigns/aids/debtrelief.html.
51. Report of the Commission for Africa (March 11, 2005). Our Common Interest http://www.commissionforafrica.org/english/report/ thereport/cfafullreport.pdf.
52. Report of the Commission on Macroeconomics and Health (December 20, 2001). Macroeconomics and Health: Investing in Health for Economic Development. http://www.who.int/whosis/cmh/cmh_report/e/ report.cfm?path=cmh,cmh_report&language=english50.
53. Report of the United Nations General Assembly Special Session (UNGASS) on HIV/AIDS (June 2001). http://www.hc-sc.gc.ca/datapcb/iad/ih_ungass-e.htm.
54. Sachs J. (2004). Developing Africa's economy. Doing the sums on Africa. The Economist http://www.economist.com/world/africa/ PrinterFriendly.cfm?Story_ID=2685783&ppv=1.
55. Salomon JA, Hogan DR, Stover J, Stanecki KA, Walker N, Ghys PD, Schwartländer B. (2005). Integrating HIV Prevention and Treatment: From Slogans to Impact. PLoS Medicine 2: 50-56 http://www.plosmedicine.org.
56. State Council AIDS Working Committee office and UN Theme Group on HIV/AIDS in China. A joint assessment of HIV/AIDS prevention, Treatment and care in China (2004). December 1, 2004.
57. TRIPS and affordable access to medicines and life saving drugs (21 May 2001). WHA 54.10, 54th World Health Assembly http://www.commin.nic.in/doc/wtotrips3.htm.
58. UNAIDS 4th Global Report on AIDS epidemic (2004). http://www.unaids.org/bangkok2004/GAR2004_pdf/ UNAIDSGlob alReport2004_en.pdf.
59. United Nations High Commissioner for Human Rights (April 2001). Access to medicine in the context of pandemics such as HIV/AIDS, Commission on Human Rights resolution 2002/32 http://www.unhchr.ch/huridocda/huridoca.nsf.
60. Wang S. (2003). People's health matters too http://www.Chinastudygroup.org/article/60/ (originally published in the June 2003 issue of the Journal Dushu).
61. World Health Organisation (2005). 3by5 Progress Report, June 2005 http://www.who.int/3by5/fullreportJune2005.pdf.
62. World Health Organisation (2005). 3by5 Progress Report, December 2004 http://www.who.int/3by5/en/ProgressReportfinal.pdf.
63. World Health Organisation. The World Medicines Situation (2004). www.who.int/medicines/organization/par/World_Medicines_Situation.pdf.
64. WHO model web site for Drug Regulatory Authorities (2004). www.who.int/ medicines/organization/qsm/activities/drugregul/dramodelweb.shtml#1.
65. WHO pre-qualification project (2004). http://mednet3.who.int/prequal/.
66. World Health Organization. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for regulatory authorities (1998). http://www.who.int/medicines/library/qsm/manual-on-marketing/ who-dmp-rgs-985.doc.
67. World Trade Organisation (2005). Overwiew: the TRIPS Agreement http://www.wto.org/English/tratop_e/trips_e/intel2_e.htm.
68. WTO Decision of the General Council on the Implementation of paragraph 6 of the Doha Declaration (30 August 2003) http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm.
69. Wu Y. (18 March 2005). The Chinese government is ready to work with the global business community to combat HIV/AIDS (China's Vice Premier speech at the Joint Summit on Business and AIDS held in Beijing by the Chinese Ministry of Health and Global Business Coalition-GBC on HIV/AIDS). http://www.businessfightsaids.org/site/ pp.asp?c=nmK0LaP6E&b=202265&printmode=l.
70. www.patentoffice.nic.in/ipr/patent/patent_2005.pdf (April 5th, 2005).
71. YaleGlobal Online (2004). Retro-virals: Major Pact for Cheap Drugs http://yaleglobal.yale.edu/article.print?id=4240.
72. Ying N, Mei S, Li L, Wei F, Zhang L, Cao Y. (2003) Study on the epidemiology and distribution of Human Immunodeficiency Virus-1 and hepatitis C Virus infection among intravenous drug users and illegal blood donors in China. Chinese Journal of Epidemiology 24; 11: 962-965.
73. Zhang L, Chen Z, Cao Y, Yu J, Li G, Yu W, Yin N, Mei S, Li L, Balfe P, He T, Ba L, Zhang F, Lin H-H, Yuen M-F, Lai C-L, Ho DD. (2004). Molecular Characterization of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus in Paid Blood Donors and Injection Drug Users in China. Journal of Virology 78: 13591-13599.
74. Zhuang K, Gui X, Su B, Tien P, Chen Z, Zhang L. (2003). High Prevalence of HIV Infection Among Women and Their Children in Henan Province, China. Journal of Acquired Immune Deficiency Syndromes. 33: 649-651.